Taipei, Taiwan, July 10, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company based in Taiwan, has reported its unaudited consolidated revenue for June 2024 at NT$1,114 million. The company recorded NT$4,743 million in revenue for 2Q24, reflecting a 13% quarter-over-quarter (QoQ) increase and a 6.8% year-over-year (YoY) growth. This performance is attributed to robust shipments of Lenalidomide and expanded business operations in Southeast Asia.
In 2Q24, Lotus's export revenue experienced a significant 29% QoQ rise and an 8% YoY increase, driven mainly by substantial shipments of Lenalidomide to major markets in the US and EU. Despite the competition from new generic launch, Buprenorphine/Naloxone achieved a notable 5% QoQ growth in 2Q24. Revenue from Asia in 2Q24 remained on par with 1Q24 levels. Year to date, Lotus's oncology product portfolio, including Lenalidomide, Alimta, Enzalutamide, and Zepzelca, has shown strong double-digit growth. Other key products such as Cialis, Aclasta, and Benzonatate continue to exhibit substantial growth.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com